" class="no-js "lang="en-US"> AviadoBio - Medtech Alert
Wednesday, March 27, 2024
AviadoBio | PTF

AviadoBio

About AviadoBio

AviadoBio
AviadoBio’s mission is to develop and deliver potentially transformative gene therapies for people living with devastating neurodegenerative diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Through a deep understanding of the brain and suite of proprietary gene therapy platforms and delivery technologies, AviadoBio is working relentlessly to overcome the challenges of delivering the right drug to the right place. Its innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. AviadoBio was founded on pioneering research from King’s College London and the UK Dementia Research Institute and has a leadership team with extensive gene therapy development, delivery and commercialization experience which uniquely positions the Company for success in bringing transformative medicines to patients.

Related Story

AviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology

February 23 2023

AviadoBio, a pioneering gene therapy company developing and delivering transformative medicines for neurodegenerative disorders and […]

AviadoBio Announces Appointment of Jeff Goater as Chair of the Board of Directors

February 1 2023

AviadoBio, a pioneering, pre-clinical stage gene therapy company focused on developing and delivering transformative medicines […]